On the other hand, strong evidence is accumulating to consider PD-L1 expression as a likely strong prognosticator in patients with CCRCC not only in metastatic cases receiving anti-PD-1 antibodies, but also receiving sunitinib or pazopanib [33]. Here, CD274 is linked to nonpapillary renal cell carcinoma.